NCT03444753
Recruiting
February 23, 2018
December 1, 2021
Brief summary:
The purpose of this study is to determine whether BMS-986299 both by itself and in combination with Nivolumab and Ipilimumab is safe and tolerable in the treatment of advanced solid tumors. In addition, the ability of study drugs to stimulate an immune response against cancer will be investigated.
N/A
Arm | Intervention/treatment |
---|---|
Experimental: Arm A BMS-986299 |
Drug: BMS-986299 Specified dose on specified day |
Experimental: Arm B BMS-986299 in combination with nivolumab and ipilimumab |
Drug: BMS-986299 Specified dose on specified day Biological: Nivolumab Specified dose on specified day Biological: Ipilimumab Specified dose on specified day |
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: Histologically or cytologically confirmed advanced/metastatic solid tumor and refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for the condition of the participant IO therapy resistant or insensitive tumors Have at least 2 tumor lesions accessible for biopsy Eastern Cooperative Oncology Group Performance Status of 0 or 1 Exclusion Criteria: Primary CNS malignancy Participants with other active malignancy requiring concurrent intervention Uncontrolled or significant cardiovascular disease Other protocol defined inclusion/exclusion criteria could apply
Contact: Recruiting sites have contact information. Please contact the sites directly. If there is no contact information please email: Clinical.Trials@bms.com
Contact: First line of the email MUST contain NCT # and Site #.
United States, California
University Of California San Diego Moores Cancer Center
La Jolla
United States, California
Local Institution
Orange
United States, California
University of California Davis Medical Center
Sacramento
United States, Connecticut
Local Institution
New Haven
United States, Michigan
Local Institution
Detroit
United States, Missouri
Washington University
Saint Louis
United States, Oregon
Local Institution
Portland
United States, Pennsylvania
Local Institution
Pittsburgh
United States, Texas
MD Anderson Cancer Center
Houston
Bristol-Myers Squibb
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb